Ipsen Boosts Oncology Pipeline with Merrimack’s Assets
By Jasmine Kalsi & Arun Manohar
Pharma Deals Review: Vol 2017 Issue 2 (Table of Contents)
Published: 23 Feb-2017
DOI: 10.3833/pdr.v2017.i2.2226 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In order to boost its oncology portfolio, Ipsen has entered into an agreement to acquire Merrimack’s pancreatic cancer drug Onivyde® (irinotecan liposome injection) and its Doxil generic, along with its commercial and marketing infrastructure for up to US$1B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS